Barclays’s Travere Therapeutics TVTX Stock Holding History

Barclays’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.1M	Buy	610,600 +398,600	+188%	+$11.9M	﹤0.01%	1144
2025 Q4	$8.1M	Buy	+212,000	New	+$6.89M	﹤0.01%	1853
2024 Q2	–	Sell	-112,000	Closed	-$864K	–	5304
2024 Q1	$864K	Sell	112,000 -56,000	-33%	-$472K	﹤0.01%	3235
2023 Q4	$1.51M	Buy	+168,000	New	+$1.22M	﹤0.01%	3136
2019 Q3	–	Sell	-200	Closed	-$4K	–	7135
2019 Q2	$4K	Sell	200 -800	-80%	-$15.8K	﹤0.01%	6736
2019 Q1	$23K	Sell	1,000 -2,500	-71%	-$55.2K	﹤0.01%	6303
2018 Q4	$79K	Hold	3,500	–	–	﹤0.01%	5212
2018 Q3	$101K	Buy	+3,500	New	+$100K	﹤0.01%	5542
2016 Q1	–	Sell	-590,900	Closed	-$11.2M	–	6441
2015 Q4	$11.2M	Buy	+590,900	New	+$11.8M	0.01%	833
2015 Q3	–	Sell	-30,000	Closed	-$990K	–	7056
2015 Q2	$990K	Buy	+30,000	New	+$822K	﹤0.01%	2888

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's TVTX Position: Q1 2026 in Review

Barclays reduced its Travere Therapeutics (TVTX) stake by 33% in Q1 2026, selling an estimated $3.61M and leaving 248,861 shares worth $7.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1605.

Barclays first reported a position in TVTX in Q1 2014 and has held it in 43 quarters since. The position peaked at $14.7M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Barclays held 248,861 shares of Travere Therapeutics worth $7.39M as of Q1 2026.
Barclays sold 120,669 Travere Therapeutics shares in Q1 2026, an estimated $3.61M.
Travere Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1605 holding.
Barclays first reported a position in Travere Therapeutics in Q1 2014 and has held it in 43 quarters since.
Barclays's Travere Therapeutics position peaked at $14.7M in Q1 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.